• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

定义广泛中和HIV抗体的标准。

Defining criteria for broadly neutralizing HIV antibodies.

作者信息

David-Fung Elizabeth-Sharon, Belobrajdic Katherine A, Macke Jennifer P, Quackenbush Corey R, Ganguly Kumkum, Mamrosh Jennifer L

机构信息

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States.

出版信息

Front Immunol. 2025 Jul 17;16:1624020. doi: 10.3389/fimmu.2025.1624020. eCollection 2025.

DOI:10.3389/fimmu.2025.1624020
PMID:40746565
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12310620/
Abstract

Over the course of a few years, a small percentage of individuals with HIV-1 develop broadly neutralizing antibodies (bnAbs) capable of neutralizing diverse viruses. Although hundreds of antibodies with neutralizing activity against heterologous viruses have been referred to as bnAbs, there is no universally accepted numerical definition of a bnAb. Here, we will review important elements of HIV neutralizing antibodies and proposed definitions of bnAbs, as well as introduce a web-based tool, CAByN (Choose Antibodies by Neutralization), allowing users to identify antibodies meeting their numerical definitions of a bnAb from data in the Los Alamos HIV Databases CATNAP (Compile, Analyze and Tally NAb Panels) antibody neutralization database. Biological findings from use of CAByN are also presented here, including differential neutralizing activity for certain antibodies across viral clades, and identification of antibodies with suspected incomplete neutralization. Website address: http://hiv.lanl.gov/content/sequence/CABYN/CABYN.html.

摘要

在几年的时间里,一小部分感染人类免疫缺陷病毒1型(HIV-1)的个体产生了能够中和多种病毒的广泛中和抗体(bnAbs)。尽管数百种具有针对异源病毒中和活性的抗体被称为bnAbs,但目前尚无关于bnAbs的普遍接受的数值定义。在此,我们将回顾HIV中和抗体的重要要素以及bnAbs的提议定义,并介绍一个基于网络的工具CAByN(通过中和选择抗体),该工具允许用户从洛斯阿拉莫斯HIV数据库CATNAP(编译、分析和统计中和抗体组)抗体中和数据库的数据中识别符合其bnAbs数值定义的抗体。本文还展示了使用CAByN的生物学发现,包括某些抗体对不同病毒分支的差异中和活性,以及疑似不完全中和抗体的鉴定。网站地址:http://hiv.lanl.gov/content/sequence/CABYN/CABYN.html 。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/9f271d4f27fb/fimmu-16-1624020-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/4b8002079992/fimmu-16-1624020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/3a740a8af67a/fimmu-16-1624020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/190265b5b4b1/fimmu-16-1624020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/33278db6d4ed/fimmu-16-1624020-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/9f271d4f27fb/fimmu-16-1624020-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/4b8002079992/fimmu-16-1624020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/3a740a8af67a/fimmu-16-1624020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/190265b5b4b1/fimmu-16-1624020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/33278db6d4ed/fimmu-16-1624020-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db3d/12310620/9f271d4f27fb/fimmu-16-1624020-g005.jpg

相似文献

1
Defining criteria for broadly neutralizing HIV antibodies.定义广泛中和HIV抗体的标准。
Front Immunol. 2025 Jul 17;16:1624020. doi: 10.3389/fimmu.2025.1624020. eCollection 2025.
2
Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies.成人与婴儿传播/奠基者HIV-1 C型病毒对广泛中和单克隆抗体的中和敏感性存在差异。
PLoS Pathog. 2025 Jun 23;21(6):e1013245. doi: 10.1371/journal.ppat.1013245. eCollection 2025 Jun.
3
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.HIV-1广谱中和抗体三联组合的安全性及抗病毒效果:一项1/2a期试验
Nat Med. 2024 Dec;30(12):3534-3543. doi: 10.1038/s41591-024-03247-5. Epub 2024 Sep 12.
4
Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.1型人类免疫缺陷病毒预防单克隆抗体早期临床试验中的剂量探索
Clin Trials. 2025 Aug;22(4):442-451. doi: 10.1177/17407745251347280. Epub 2025 Jul 5.
5
Development of screening assays for use of broadly neutralizing antibodies in people with HIV.用于 HIV 感染者的广谱中和抗体的筛选检测方法的开发。
Curr Opin HIV AIDS. 2023 Jul 1;18(4):171-177. doi: 10.1097/COH.0000000000000798. Epub 2023 May 9.
6
Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti-HIV-1 Antibodies.用于广泛中和抗HIV-1抗体的中和敏感性筛选试验的评估及真实世界经验
J Infect Dis. 2025 Feb 20;231(2):424-434. doi: 10.1093/infdis/jiae486.
7
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development.杜克艾滋病疫苗研究联盟诱导 HIV 广谱中和抗体的进展。
Curr Opin HIV AIDS. 2023 Nov 1;18(6):300-308. doi: 10.1097/COH.0000000000000820. Epub 2023 Sep 25.
8
Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.N6LS的安全性和药代动力学,一种用于治疗HIV的广泛中和单克隆抗体:一项在健康成年人中进行的1期开放标签剂量递增研究。
Lancet HIV. 2025 Jul;12(7):e485-e495. doi: 10.1016/S2352-3018(25)00041-4. Epub 2025 May 20.
9
HIV-1 broadly neutralizing antibodies demonstrate a high propensity for binding to heme.HIV-1广谱中和抗体表现出与血红素结合的高度倾向。
J Immunol. 2025 Jun 1;214(6):1370-1383. doi: 10.1093/jimmun/vkaf015.
10
Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.多种鼠类疫苗接种揭示了针对融合肽的不同抗体类别和肽长度的变化,以提高 HIV 中和能力。
J Virol. 2023 May 31;97(5):e0160422. doi: 10.1128/jvi.01604-22. Epub 2023 Apr 26.

本文引用的文献

1
HIV Vaccine Development at a Crossroads: New B and T Cell Approaches.艾滋病疫苗研发处于十字路口:B细胞和T细胞新方法
Vaccines (Basel). 2024 Sep 12;12(9):1043. doi: 10.3390/vaccines12091043.
2
Germinal centers output clonally diverse plasma cell populations expressing high- and low-affinity antibodies.生发中心输出具有高亲和性和低亲和性抗体的克隆多样性浆细胞群体。
Cell. 2023 Dec 7;186(25):5486-5499.e13. doi: 10.1016/j.cell.2023.10.022. Epub 2023 Nov 10.
3
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
优化用于 HIV 预防的组合广泛中和抗体的临床用药剂量。
PLoS Comput Biol. 2022 Apr 6;18(4):e1010003. doi: 10.1371/journal.pcbi.1010003. eCollection 2022 Apr.
4
To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1.是否存在广谱中和抗体:定义针对 HIV-1 的广谱中和抗体。
Front Immunol. 2021 Oct 19;12:708227. doi: 10.3389/fimmu.2021.708227. eCollection 2021.
5
Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody.表面基质筛选鉴定出能提高近泛 HIV-1 中和抗体效力的半特异性相互作用。
Cell Rep. 2018 Feb 13;22(7):1798-1809. doi: 10.1016/j.celrep.2018.01.023.
6
Neutralization tiers of HIV-1.HIV-1 的中和层级。
Curr Opin HIV AIDS. 2018 Mar;13(2):128-136. doi: 10.1097/COH.0000000000000442.
7
Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.针对具有传播奠基者Env的HIV-1细胞间传播的广谱中和抗体的效力降低及中和不完全
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02425-16. Print 2017 May 1.
8
Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G.三聚体HIV-1包膜结构定义了A、B和G亚型的聚糖屏蔽层。
Cell. 2016 May 5;165(4):813-26. doi: 10.1016/j.cell.2016.04.010. Epub 2016 Apr 21.
9
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.用于预防和治疗HIV-1 C亚型感染的广谱中和抗体的最佳组合
PLoS Pathog. 2016 Mar 30;12(3):e1005520. doi: 10.1371/journal.ppat.1005520. eCollection 2016 Mar.
10
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies.HIV广谱中和单克隆抗体的不完全中和及与S形中和曲线的偏差
PLoS Pathog. 2015 Aug 12;11(8):e1005110. doi: 10.1371/journal.ppat.1005110. eCollection 2015 Aug.